The Innovative Medicines Initiative Joint Undertaking (IMI2 JU) project Immune-Image will study immune cells in vivo using non-invasive and clinically applicable high-end imaging techniques to visualize and study such cells before, during and after immunotherapy treatments. This will allow for the selection of the right immunotherapy treatment for the right patient at the right time. Insights gathered during this project could also be used to develop new drugs to help patients for which the current immunotherapies are ineffective.
The consortium for this project, which will run for an initial period of 5 years, consists of 10 top European academic institutions, 4 small-to-medium sized enterprises, 1 patient organization and 7 pharmaceutical companies, and will be supervised by scientific and ethical boards. Lygature will lead the data management efforts in the project based on previous experience from the TraIT and Health-RI programs.
For more information on the project, read the full press-release.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831514. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.